Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.37 |
| ▸ | DRD4 | P21917 | 9/20 | 0.37 |
| ▸ | DRD3 | P35462 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718893 | 0.92 | DRD2 (0.40) | DRD2DRD4DRD3ALDH1A1CCND1 | |
| SCHEMBL3720561 | 0.89 | DRD2 (0.37) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL4186178 | 0.88 | GPR39 (0.38) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL3721695 | 0.86 | LRRK2 (0.41) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL3720795 | 0.85 | DRD2 (0.38) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL3719893 | 0.84 | GSK3B (0.43) | DRD2DRD4DRD3WNT1DYRK1A | |
| SCHEMBL3721740 | 0.83 | TGFBR1 (0.42) | DRD2DRD4DRD3ALDH1A1CCND1 | |
| SCHEMBL3729038 | 0.82 | DRD2 (0.37) | DRD2DRD4DRD3ALDH1A1MAPT | |
| SCHEMBL3722539 | 0.81 | DRD2 (0.41) | DRD2DRD4DRD3ALDH1A1DYRK1A | |
| SCHEMBL3721456 | 0.80 | DRD2 (0.40) | DRD2DRD4DRD3ALDH1A1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | DRD2 2577/4885DRD4 2342/4885DRD3 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.